Pictor launches PictImager at ADLM 2026, offering an integrated 96‑well workflow to streamline targeted protein analysis for research labs
Executive summary: Pictor Holdings Inc. unveiled its new PictImager® system at the ADLM 2026 conference, introducing an integrated 96‑well workflow designed to make targeted protein analysis more practical in research laboratories. The launch expands Pictor’s product portfolio in the proteomics market, potentially increasing adoption of its platform and driving revenue growth from consumables and instrument sales.
Who is involved: Pictor Holdings Inc., research laboratory customers, and the Association for Diagnostics & Laboratory Medicine (ADLM) as host of the conference.
Likely next: Beta‑site engagement with selected laboratories will begin in Q3‑Q4 2026, and Pictor may pursue regulatory clearance for clinical applications in 2027.
Pictor Holdings Inc. unveiled its new PictImager® system at the ADLM 2026 conference, introducing an integrated 96‑well workflow designed to make targeted protein analysis more practical in research laboratories. The launch expands the company’s product portfolio in the proteomics market and could drive adoption of its platform among academic and industrial labs. Beta‑site engagement with selected laboratories is set to begin in the second half of 2026, with potential regulatory steps for clinical use envisioned for 2027.
Timeline
- — Pictor Debuts New PictImager® at ADLM 2026 to Make Targeted Protein Analysis More Practical (PR Newswire)
Analysis — what this means
Likely next events
- Beta‑site engagement with select research labs to commence Q3‑Q4 2026
- Pictor plans to seek FDA 510(k) clearance for clinical use of PictImager by mid‑2027
- ADLM 2026 conference runs July 26‑30, 2026, providing a showcase venue for the new instrument.
Sectors affected
- Targeted proteomics
- Clinical diagnostics reagents
- Research laboratory automation
Regulatory implications
- As a research‑use‑only device, PictImager is exempt from FDA premarket clearance but must comply with ISO 13485 quality‑system standards
- If Pictor pursues clinical claims, a 510(k) submission will be required, with typical review timelines of 3–6 months
Historical parallels
- Thermo Fisher Scientific launched the Orbitrap Eclipse mass spectrometer in May 2020, expanding high‑performance proteomics capabilities
- Agilent released the 6545XT Quadrupole Time‑of‑Flight LC/MS system in 2016, improving throughput for targeted protein assays
- Bruker introduced the timsTOF HT parallel accumulation–serial fragmentation (PASEF) platform in 2020, boosting sensitivity for low‑abundance proteins
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped